222 related articles for article (PubMed ID: 37870091)
1. Systematic characterization of antibody-drug conjugate targets in central nervous system tumors.
Coy S; Lee JS; Chan SJ; Woo T; Jones J; Alexandrescu S; Wen PY; Sorger PK; Ligon KL; Santagata S
Neuro Oncol; 2024 Mar; 26(3):458-472. PubMed ID: 37870091
[TBL] [Abstract][Full Text] [Related]
2. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
3. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.
Schlam I; Moges R; Morganti S; Tolaney SM; Tarantino P
Crit Rev Oncol Hematol; 2023 Oct; 190():104090. PubMed ID: 37562695
[TBL] [Abstract][Full Text] [Related]
4. B7-H3 in Brain Malignancies: Immunology and Immunotherapy.
Guo X; Chang M; Wang Y; Xing B; Ma W
Int J Biol Sci; 2023; 19(12):3762-3780. PubMed ID: 37564196
[TBL] [Abstract][Full Text] [Related]
5. Development of a MMAE-based antibody-drug conjugate targeting B7-H3 for glioblastoma.
Mao Y; Wei D; Fu F; Wang H; Sun Z; Huang Z; Wang Y; Zhang G; Zhang X; Jiang B; Chen H
Eur J Med Chem; 2023 Sep; 257():115489. PubMed ID: 37235999
[TBL] [Abstract][Full Text] [Related]
6. Antibody-drug conjugates in solid tumors: a look into novel targets.
Criscitiello C; Morganti S; Curigliano G
J Hematol Oncol; 2021 Jan; 14(1):20. PubMed ID: 33509252
[TBL] [Abstract][Full Text] [Related]
7. PF-06804103, A Site-specific Anti-HER2 Antibody-Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers.
Graziani EI; Sung M; Ma D; Narayanan B; Marquette K; Puthenveetil S; Tumey LN; Bikker J; Casavant J; Bennett EM; Charati MB; Golas J; Hosselet C; Rohde CM; Hu G; Guffroy M; Falahatpisheh H; Finkelstein M; Clark T; Barletta F; Tchistiakova L; Lucas J; Rosfjord E; Loganzo F; O'Donnell CJ; Gerber HP; Sapra P
Mol Cancer Ther; 2020 Oct; 19(10):2068-2078. PubMed ID: 32747418
[TBL] [Abstract][Full Text] [Related]
8. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
Chou J; Trepka K; Sjöström M; Egusa EA; Chu CE; Zhu J; Chan E; Gibb EA; Badura ML; Contreras-Sanz A; Stohr BA; Meng MV; Pruthi RS; Lotan Y; Black PC; Porten SP; Koshkin VS; Friedlander TW; Feng FY
Eur Urol Oncol; 2022 Dec; 5(6):714-718. PubMed ID: 35216942
[TBL] [Abstract][Full Text] [Related]
9. Claudin-6 is a nonspecific marker for malignant rhabdoid and other pediatric tumors.
Sullivan LM; Yankovich T; Le P; Martinez D; Santi M; Biegel JA; Pawel BR; Judkins AR
Am J Surg Pathol; 2012 Jan; 36(1):73-80. PubMed ID: 21989342
[TBL] [Abstract][Full Text] [Related]
10. Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors.
Nelson BE; Meric-Bernstam F
Annu Rev Med; 2024 Jan; 75():31-48. PubMed ID: 37758237
[TBL] [Abstract][Full Text] [Related]
11. Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress.
Rosner S; Valdivia A; Hoe HJ; Murray JC; Levy B; Felip E; Solomon BJ
Am Soc Clin Oncol Educ Book; 2023 May; 43():e389968. PubMed ID: 37163707
[TBL] [Abstract][Full Text] [Related]
12. Utility of apparent diffusion coefficient ratios in distinguishing common pediatric cerebellar tumors.
Gimi B; Cederberg K; Derinkuyu B; Gargan L; Koral KM; Bowers DC; Koral K
Acad Radiol; 2012 Jul; 19(7):794-800. PubMed ID: 22513110
[TBL] [Abstract][Full Text] [Related]
13. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
Lambert JM; Morris CQ
Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465
[TBL] [Abstract][Full Text] [Related]
14. Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?
Nicolò E; Repetto M; Boscolo Bielo L; Tarantino P; Curigliano G
Cancer J; 2022 Nov-Dec 01; 28(6):436-445. PubMed ID: 36383906
[TBL] [Abstract][Full Text] [Related]
15. Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles.
Fenton MA; Tarantino P; Graff SL
Curr Oncol; 2023 Nov; 30(12):10211-10223. PubMed ID: 38132377
[TBL] [Abstract][Full Text] [Related]
16. Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer.
Najminejad Z; Dehghani F; Mirzaei Y; Mer AH; Saghi SA; Abdolvahab MH; Bagheri N; Meyfour A; Jafari A; Jahandideh S; Gharibi T; Amirkhani Z; Delam H; Mashatan N; Shahsavarani H; Abdollahpour-Alitappeh M
Mol Ther; 2023 Jul; 31(7):1874-1903. PubMed ID: 36950736
[TBL] [Abstract][Full Text] [Related]
17. Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability.
Feng Y; Lee J; Yang L; Hilton MB; Morris K; Seaman S; Edupuganti VVSR; Hsu KS; Dower C; Yu G; So D; Bajgain P; Zhu Z; Dimitrov DS; Patel NL; Robinson CM; Difilippantonio S; Dyba M; Corbel A; Basuli F; Swenson RE; Kalen JD; Suthe SR; Hussain M; Italia JS; Souders CA; Gao L; Schnermann MJ; St Croix B
Cell Rep; 2023 Dec; 42(12):113503. PubMed ID: 38019654
[TBL] [Abstract][Full Text] [Related]
18. 'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review.
Verma S; Breadner D; Raphael J
Curr Oncol; 2023 Apr; 30(4):4329-4350. PubMed ID: 37185443
[TBL] [Abstract][Full Text] [Related]
19. Future potential targets of antibody-drug conjugates in breast cancer.
Corti C; Boscolo Bielo L; Schianca AC; Salimbeni BT; Criscitiello C; Curigliano G
Breast; 2023 Jun; 69():312-322. PubMed ID: 36996620
[TBL] [Abstract][Full Text] [Related]
20. Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response.
Bosi C; Bartha Á; Galbardi B; Notini G; Naldini MM; Licata L; Viale G; Mariani M; Pistilli B; Ali HR; André F; Piras M; Callari M; Barreca M; Locatelli A; Viganò L; Criscitiello C; Pusztai L; Curigliano G; Győrffy B; Dugo M; Bianchini G
Eur J Cancer; 2023 Dec; 195():113379. PubMed ID: 37913680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
